Hottest Stories on Wall Street: Valero Energy Partners LP (NYSE:VLP), eHealth (NASDAQ:EHTH), Aeterna Zentaris (NASDAQ:AEZS), Itau Unibanco Holding SA (NYSE:ITUB)

RTI Surgical Inc. (NASDAQ:RTIX) shares decreased -4.19% in last trading session and ended the day at $3.20. RTIX Gross Margin is 53.10% and its has a return on assets of 2.20%. RTI Surgical Inc. (NASDAQ:RTIX) quarterly performance is -37.01%.

RTI Surgical Inc. (NASDAQ:RTIX) preliminary unaudited fourth quarter and full year 2015 revenue. Worldwide revenues were $76.1 million for the fourth quarter of 2015 compared to revenues of $70.9 million for the fourth quarter of 2014. Domestic revenues for the fourth quarter of 2015 were $70.6 million compared to revenues of $65.4 million for the fourth quarter 2014.

Valero Energy Partners LP (NYSE:VLP) ended the last trading day at $42.69. Company weekly volatility is calculated as 7.48% and price to cash ratio as 56.16. Valero Energy Partners LP (NYSE:VLP) showed a weekly performance of -8.80%.

Valero Energy Partners LP (NYSE:VLP) has acquired a 50 percent interest in a pipeline that runs from strategic storage terminals in Oklahoma to Memphis, Tennessee.

On 19 January, eHealth, Inc. (NASDAQ:EHTH) shares decreased -3.66% and was closed at $9.73. EHTH EPS growth in last 5 year was -28.00%. eHealth, Inc. (NASDAQ:EHTH) year to date (YTD) performance is -2.51%.

On 14 January, eHealth, Inc. (NASDAQ:EHTH) and Baystate Health, one of the largest integrated healthcare systems in New England, are pleased to announce that users of the Pioneer Valley Information Exchange (PVIX) can now access diagnostic quality images for radiology exams that have been performed at six locations across western Massachusetts.

Aeterna Zentaris Inc. (NASDAQ:AEZS) shares moved up 16.85% in last trading session and ended the day at $3.12. AEZS has a return on assets of -65.60%. Aeterna Zentaris Inc. (NASDAQ:AEZS) quarterly performance is -48.00%.

Aeterna Zentaris Inc. (NASDAQ:AEZS) announced that it concluded a successful meeting of the clinical investigators for the confirmatory Phase 3 trial of Macrilen™ (macimorelin), a novel orally-active ghrelin agonist for use in evaluating adult growth hormone deficiency (“AGHD”). As a result, the Company is confident that it will complete the confirmatory trial by year-end 2016.

Itau Unibanco Holding SA (ADR) (NYSE:ITUB) shares decreased -1.37% in last trading session and ended the day at $5.76. ITUB has a return on assets of 2.30%. Itau Unibanco Holding SA (ADR) (NYSE:ITUB) quarterly performance is -17.92%.

Itau Unibanco Holding SA (ADR) (NYSE:ITUB) has inked a deal to acquire the struggling investment bank, Banco BTG Pactual S.A.’s entire stake in debt collection company – Recovery do Brasil Consultoria S.A.